Drugs / XER-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07157033 | Jan 2026 → Jul 2029 expected | pancreatic ductal adenocarcinoma | Xerient Pharma | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XER-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07157033 ↗ |
| Known as | Amifostine | “XER-001 (Amifostine for nasoduodenal delivery)” NCT07157033 ↗ |
| Route | Other | “nasoduodenal administration of XER-001” NCT07157033 ↗ |